To address regional disparity, the investigators propose a tailored perioperative strategy for East Asian patients, combining neoadjuvant FLOT plus durvalumab, followed by adjuvant TS-1 plus durvalumab. This approach seeks to balance efficacy, immunologic synergy, and treatment tolerability, offering a more practical regimen for Eastern populations.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up visits.
Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.
Age ≥18 years at the time of screening.
Patients with peritoneal dissemination (including tumor cells in peritoneal fluid) or distant metastasis
Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor
History of allogeneic organ transplantation.
Patients with vitiligo or alopecia